Please login to the form below

Not currently logged in

moderate-to-severe atopic dermatitis

This page shows the latest moderate-to-severe atopic dermatitis news and features for those working in and with pharma, biotech and healthcare.

Sanofi/Regeneron’s Dupixent shows promise in atopic hand and foot dermatitis

Sanofi/Regeneron’s Dupixent shows promise in atopic hand and foot dermatitis

Sanofi and Regeneron’s Dupixent (dupilumab) was associated with significant improvements in moderate-to-severe atopic hand and foot dermatitis symptoms, according to phase 3 results presented at the American Academy ... The phase 3 trial evaluated

Latest news

More from news
Approximately 1 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Meanwhile, phase 2b results for upadacitinib showed that the drug was able to improve skin lesions and itching in patients with moderate-to- severe atopic dermatitis (eczema) across all doses tested, ... Risankizumab is almost inevitably going to have a

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts


Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

The speed of science and the pace of comms
Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
Improving cardiovascular disease care and awareness
Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......